Research Articles

Compiled for your convenience are articles on bone marrow failure research and treatment from the world’s major journals on hematology / oncology.

Article Title Original Publication Date Journal Sort ascending Bone Marrow Disease
Advances in the management of higher-risk myelodysplastic syndromes: future prospects Leukemia & Lymphoma Myelodysplastic Syndromes (MDS)
Clonal evolution in aplastic anemia: failed tumor surveillance or maladaptive recovery? Leukemia & Lymphoma Aplastic Anemia
Eat and be healthy: nutritional status in myelodysplastic syndromes Leukemia & Lymphoma Myelodysplastic Syndromes (MDS)
Phase II study of the clinical efficacy and safety of tosedostat in patients with myelodysplastic syndromes (MDS) after failure of hypomethylating agent-based therapy Leukemia & Lymphoma Myelodysplastic Syndromes (MDS)
Optimal timing of allogeneic hematopoietic stem cell transplant in MDS Leukemia & Lymphoma Myelodysplastic Syndromes (MDS)
Consensus minimum hemoglobin level above which patients with myelodysplastic syndromes can safely forgo transfusions Leukemia & Lymphoma Myelodysplastic Syndromes (MDS)
Sustained benefits of imetelstat on patient-reported fatigue in patients with lower-risk myelodysplastic syndromes ineligible for, or relapsed/refractory to, erythropoiesis-stimulating agents and high transfusion burden in the phase 3 IMerge study Leukemia & Lymphoma Myelodysplastic Syndromes (MDS)
Clonal dynamics of aplastic anemia/paroxysmal nocturnal hemoglobinuria Leukemia & Lymphoma Aplastic Anemia
Raising the bar for lower-risk myelodysplastic syndromes Leukemia & Lymphoma Myelodysplastic Syndromes (MDS)
Venetoclax and hypomethylating agent therapy in high risk myelodysplastic syndromes: a retrospective evaluation of a real-world experience Leukemia & Lymphoma Myelodysplastic Syndromes (MDS)

Website Feedback

Please use this feedback form to report website issues only. For other issues concerning patients and families, please email help@aamds.org or use the Patient and Family Helpline here.